Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase I trial identifies the side effects and best dose of DS-8201a and olaparib in treating patients with HER2-expressing cancers that have spread to other places in the body or cannot be removed by surgery or ovarian cancer that remains despite treatment with a platinum treatment (platinum resistant). Olaparib is a drug that blocks an enzyme involved in many cell functions, including the repair of deoxyribonucleic acid (DNA) damage. Blocking this enzyme may help keep tumor cells from repairing their damaged DNA, causing them to die. DS-8201a is an antibody-drug conjugate. This agent has two components: an antibody component and a chemotherapy component. The antibody component is attached to the chemotherapy molecules. Upon administration of DS-8201a, the antibody targets and binds to tumor cells that have abundant HER2 (human-epidermal growth factor receptor 2), which is a protein on the surface of some tumor cells. The chemotherapy then enters the cells and blocks DNA replication in the tumor cells with abundant HER2, causing them to die. Giving DS-8201a and olaparib may shrink or stabilize the cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjenci z potwierdzonym laboratoryjnie nowotworem, który jest zaawansowany (przerzutowy lub nieoperacyjny) i na który standardowe leczenie jest nieskuteczne.
- •Pacjenci z guzami posiadającymi białko HER2 (wyrażającymi HER2) potwierdzonymi badaniami laboratoryjnymi.
- •Pacjentki z rakiem jajnika odpornym na platynę (choroba nasila się w ciągu 6 miesięcy od ostatniej dawki leczenia platyną).
- •Rak jajnika musi wykazywać ekspresję HER2 na poziomie 1+.
- •Musibyeć co najmniej jedna zmiana chorobowa, która nadaje się do biopsji bez większego ryzyka dla pacjenta.
- •Choroba pacjenta musi być możliwa do oceny lub zmierzenia według określonych kryteriów (RECIST 1.1).
- •Pacjenci musieli przejść co najmniej jedną linię wcześniejszego leczenia chemioterapią.
✗ Disqualifies
- •Pacjenci z nowotworami, które nie posiadają białka HER2 (ujemne HER2) lub których status HER2 jest nieznany.
- •Pacjentki z rakiem jajnika, który jest wrażliwy na platynę (nie jest odporny).
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 10, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (13)
Mayo Clinic Hospital in Arizona
Phoenix, United States
UM Sylvester Comprehensive Cancer Center at Coral Gables
Coral Gables, United States
UM Sylvester Comprehensive Cancer Center at Deerfield Beach
Deerfield Beach, United States
UM Sylvester Comprehensive Cancer Center at Doral
Doral, United States
Mayo Clinic in Florida
Jacksonville, United States
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, United States
UM Sylvester Comprehensive Cancer Center at Kendall
Miami, United States
UM Sylvester Comprehensive Cancer Center at Plantation
Plantation, United States
Emory University Hospital Midtown
Atlanta, United States
Emory University Hospital/Winship Cancer Institute
Atlanta, United States
Dana-Farber Cancer Institute
Boston, United States
Mayo Clinic in Rochester
Rochester, United States
UPMC Hillman Cancer Center
Pittsburgh, United States
Trial contact
Site Public Contact
Abdulrahman Sinno
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Andrea E. Wahner Hendrickson
PRINCIPAL_INVESTIGATOR
Site Public Contact
Kristen Starbuck
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Elizabeth K. Lee
PRINCIPAL_INVESTIGATOR
Site Public Contact
Sarah E. Taylor
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.